 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Arrowhead Pharmaceuticals, Inc. (ARWR) develops medicines for the treatment of intractable diseases in the United States.
The company is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target.ny's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics.
On May 8th, the firm reported its earnings. The Company reported 2nd Quarter March 2019 earnings of $0.24 per share on revenue of $48.1 million. The consensus earnings estimate was $0.22 per share on revenue of $44.6 million. Since then shares have formed a bullish "double bottom formation" and are expected to move higher out of this formation.
Entry Point: $26.75
Stop Loss: $25.40
Trading Range: $10.41 to $28.84
Target Price: $29.42
ARWR closed at $29.90
